FY2024 EPS Estimates for BrainsWay Increased by Analyst

BrainsWay Ltd. (NASDAQ:BWAY) – Analysts at Northland Capmk boosted their FY2024 earnings per share (EPS) estimates for shares of BrainsWay in a research report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.06 per share for the year, up from their previous estimate of $0.05. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

BWAY has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research note on Monday, October 21st. Northland Securities lifted their price objective on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research note on Thursday, October 3rd.

BrainsWay Stock Down 6.8 %

BWAY stock opened at $9.04 on Thursday. The business has a fifty day moving average of $9.16 and a two-hundred day moving average of $7.44. The stock has a market cap of $150.79 million, a price-to-earnings ratio of 91.11 and a beta of 1.25. BrainsWay has a 52-week low of $3.80 and a 52-week high of $10.98.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. During the same quarter last year, the firm earned ($0.01) earnings per share.

Institutional Investors Weigh In On BrainsWay

A number of institutional investors and hedge funds have recently modified their holdings of BWAY. Acadian Asset Management LLC grew its holdings in BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after buying an additional 84,371 shares during the last quarter. Good Life Advisors LLC grew its holdings in BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares during the last quarter. Perritt Capital Management Inc purchased a new position in shares of BrainsWay during the 2nd quarter worth $121,000. Rhumbline Advisers lifted its stake in shares of BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after purchasing an additional 1,695 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of BrainsWay during the 1st quarter worth $60,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.